Overview of Trimetazidina Risina

Quick Facts

Property	Description
Active ingredient	Trimetazidine dihydrochloride
Form	Modified-release (MR) tablets
Pharmacological class	Metabolic agent / Cytoprotective anti-ischemic agent
General purpose	Optimizes cardiac energy efficiency
Origin	Synthetic, Piperazine derivative

Defining Trimetazidina Risina: A Metabolic Anti-Ischemic Agent

Trimetazidina Risina is a pharmaceutical preparation whose primary active component is Trimetazidine dihydrochloride, a chemically synthetic piperazine derivative. This compound is classified as an anti-ischemic agent and is specifically grouped under "Other cardiac preparations" (C01EB15). Unlike traditional anti-ischemic medications, which alter the heart's pumping dynamics or blood flow (hemodynamic functions), Trimetazidine is fundamentally a metabolic modulator. Its categorization and therapeutic approach are intended for offering support to patients whose condition is related to metabolic stress rather than primarily circulatory factors.

Composition and Form: The Modified-Release Design

This preparation is a single-ingredient product, containing only Trimetazidine dihydrochloride alongside necessary pharmaceutical excipients used for its solid oral form. It is specifically formulated as a film-coated, modified-release (MR) tablet for oral administration. The design of the modified-release tablet is an intrinsic characteristic of this product, ensuring the slow and consistent delivery of the active substance over an extended period. This sustained presence is a critical requirement for achieving the compound's intended metabolic effects within the body.

General Purpose: Modulating Cellular Energy Efficiency

The general purpose of Trimetazidine is to improve the way the body’s cells, particularly those in the heart, generate and manage energy during conditions of stress or reduced oxygen supply (ischemia). It functions by inducing a metabolic shift, encouraging the heart cells to prioritize the consumption of glucose, a more oxygen-efficient fuel, over fatty acids. This principle of improving energy utilization is centered on the compound's effect on cellular respiration. By increasing cardiac energy efficiency and providing a cytoprotective effect, the compound helps maintain the functional integrity of vital tissues, mitigating the impact of oxygen deprivation at a fundamental cellular level.

Regulatory References

metabolic modulator

What side effects are possible with Trimetazidina Risina?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety constraints for Trimetazidine dihydrochloride, based strictly on governmental regulatory sources (e.g., Summary of Product Characteristics).

Documented Adverse Reactions

The most common adverse reactions listed in regulatory documents are generally centered on the gastrointestinal and nervous systems. Side effects are classified by frequency:

Frequency	Examples of Officially Documented Effects
Common (1 in 100 to 1 in 10 patients)	Headache, Dizziness, Nausea, Vomiting, Diarrhoea, Abdominal pain, Dyspepsia, Rash, Pruritus, Urticaria, Asthenia.
Rare (1 in 10,000 to 1 in 1,000 patients)	Palpitations, Tachycardia, Extrasystoles, Arterial Hypotension, Orthostatic hypotension, Flushing, Malaise.
Not Known (Frequency cannot be estimated)	Parkinsonian symptoms (and related movement disorders), Gait instability, Hepatitis, Agranulocytosis, Thrombocytopenia, Vertigo.

Safety and Restrictions

Serious Adverse Reaction Noted

The label documents a risk of developing or worsening Parkinsonian symptoms (including tremor and gait instability), which is classified as a serious adverse reaction. Regulatory information indicates these symptoms are typically reversible upon discontinuing the medication, with most patients recovering within four months.

Population-Specific Constraints

Trimetazidine is Contraindicated for use in individuals with existing Parkinson’s disease, parkinsonian symptoms, or severe renal impairment (Creatinine Clearance below 30 mL/min). Caution is advised for elderly patients (over 75 years) and those with moderate renal impairment, and the medication is not recommended for the pediatric population (under 18 years).

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented clinical signs, potential severe outcomes, and mandated emergency actions for Trimetazidine dihydrochloride overdose, strictly according to government regulatory sources.

Domain	Regulatory Statement
Documented Clinical Manifestations	Officially listed signs of acute overdose include hypotension (low blood pressure), flushing, and mild to moderate dizziness.
Severe Outcomes	Overdose involving high doses may be associated with life-threatening symptoms.
Antidote Status	No specific antidote is known.

Required Emergency Actions and Management

Regulatory documents explicitly mandate that individuals who suspect an overdose must seek immediate medical attention from a healthcare professional. Given the risk of severe or life-threatening symptoms associated with high-dose exposure, it is required to contact emergency services immediately upon suspicion.

Because no specific antidote is known, the management protocol outlined by regulators is strictly symptomatic and supportive treatment. This includes interventions directed toward maintaining haemodynamic stability, particularly controlling hypotension. For observation and care, hospital monitoring may be required to manage documented clinical manifestations according to official regulatory protocols.

Therapeutic Uses of Trimetazidina Risina

The primary application of Trimetazidina Risina is the symptomatic treatment of stable angina pectoris. The medication is generally applied in settings where supportive symptom management is appropriate for conditions characterized by recurrent or episodic manifestations.

It is relevant for managing symptom clusters that may become intense or disruptive, particularly episodes of chest discomfort and physical limitation due to effort. Trimetazidina Risina is commonly used in clinical settings when the symptoms require additional therapeutic support, supporting the patient during difficult episodes by easing distress.

This medication assists with maintaining functional stability and may contribute to better management of symptoms that interfere with routine physical activities, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Stable Angina Symptoms
Primary Use: Symptomatic support for stable angina pectoris.
Main Benefit: May assist with easing the overall burden of symptoms.
Usage Context: Applied for persistent symptoms requiring additional management.

Regulatory References

Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Trimetazidina Risina

The use of Trimetazidina Risina is defined by strict population eligibility rules outlined in official regulatory documents.

Contraindicated Populations (Absolute Non-Eligibility)

Category	Status and Regulatory Wording
Movement Disorders	Contraindicated in Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
Renal Function	Contraindicated in severe renal impairment (creatinine clearance below 30 mL/min).
Hypersensitivity	Contraindicated in patients with known allergy to the active substance or excipients.

Restricted and Non-Recommended Use

Category	Status and Regulatory Wording
Age Groups	Not recommended for children and adolescents (below 18 years), as safety and efficacy have not been established. Caution is formally required for elderly patients (over 75 years).
Kidney Function	Caution must be exercised in moderate renal impairment (creatinine clearance between 30 and 60 mL/min).
Reproductive Status	Use is not recommended during both pregnancy and breastfeeding.

Connection to the overall eligibility profile: Regulatory documents define eligibility by establishing definitive, absolute contraindications for patients with specific neurological conditions or severely compromised kidney function, and by formally stating that use is not recommended in all pediatric, pregnant, and lactating populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interaction patterns and restrictions as officially documented in government-approved drug labels, focusing on how co-administration with other substances is addressed by regulatory authorities.

Officially Documented Interaction Profile

Official regulatory reviews consistently indicate that no clinically significant pharmacokinetic drug-drug interactions have been identified for Trimetazidine dihydrochloride. This means that the medicine is not officially documented to significantly alter the metabolism or clearance of commonly co-administered cardiovascular agents, nor do they affect its elimination.

Absence of Metabolic Interactions: Regulatory data confirms that Trimetazidine does not possess a significant profile for interactions mediated by metabolic enzymes (e.g., CYP) or drug transporters, and thus no such interactions are noted in the official prescribing information.
Interaction with Foodstuffs: There are no documented interactions with foodstuffs. The absorption of the drug is not significantly influenced by meals, and no mandatory timing separation is required for its administration relative to food.

Pharmacodynamic and Exposure Cautions

While metabolic interactions are absent, regulatory labels include specific cautions regarding additive risks and altered exposure in certain patient groups:

Interaction Type	Official Regulatory Statement
Pharmacodynamic Additive Risk	Caution for a potential increase in the risk of falls and orthostatic hypotension when co-administered with antihypertensive treatment.
Population Exposure Change	Increased exposure to Trimetazidine is officially expected in elderly patients and those with moderate renal impairment (CrCl 30-60 mL/min) due to reduced drug clearance.

Mechanism of Action

Mitochondrial Energy Reprogramming and Efficiency

Trimetazidine exerts its effect by acting as a selective inhibitor of the mitochondrial enzyme, long-chain 3-ketoacyl Coenzyme A thiolase (LC 3-KAT), thereby partially suppressing the fatty acid beta-oxidation (FAO) pathway. This inhibition compels the heart muscle cell to switch its primary fuel source to glucose oxidation, a process that requires significantly less oxygen to generate the same amount of cellular energy (ATP). The resulting physiological consequence is an increase in myocardial energy efficiency during periods of reduced oxygen supply.

Mechanistic Cascade for Cellular Homeostasis

The metabolic shift away from FAO initiates a mechanistic cascade inside the cell. By reducing the buildup of metabolic byproducts, the drug stabilizes the internal pH and limits the excessive accumulation of protons ( H^+). This pH stabilization contributes to the preservation of the cell's ion exchange mechanisms, limiting the Ca^2+ overload that is associated with cellular distress. This mechanism supports a cytoprotective effect, helping to preserve the functional integrity of the heart cell membrane and mitochondria during states of low oxygen.

Dosage and Administration Information

How to Use Trimetazidina Risina

This section outlines the general principles of administering Trimetazidina Risina (Trimetazidine dihydrochloride 35 mg Modified-Release tablets), focusing on usage patterns, dosing, and administration conditions.

Administration Protocol

The standard protocol involves oral administration of the 35 mg modified-release tablet. The usual adult daily dose is 70 mg, achieved by taking one 35 mg tablet twice daily—once in the morning and once in the evening.

To ensure proper function of the modified-release formulation, the tablets must be swallowed whole with water and must not be crushed or chewed. Dosing must occur during meals for both the morning and evening administration, which is a key instruction for the proper intake of this medicine.

Population-Specific Use and Duration

Population Group	Standard Instruction
Standard Adult	35 mg twice daily (70 mg total daily dose).
Moderate Renal Impairment	Dose must be reduced to 35 mg once daily (one tablet) taken in the morning during breakfast.
Pediatric Population	Use is not recommended due to a lack of established data.

Trimetazidina Risina is generally used as part of a long-term therapeutic plan, but the clinical benefit of the treatment must be assessed after three months of continuous use to determine if continuation is appropriate. It is also explicitly specified that this medicine is not indicated for the initial or symptomatic treatment of acute conditions such as unstable angina or a myocardial infarction.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has examined whether Trimetazidina influences the symptoms of stable angina pectoris and how quickly any changes may be observed. Trials often evaluate the drug as an add-on treatment for patients whose symptoms are not adequately controlled by first-line therapies (such as beta-blockers or calcium channel blockers).

Symptom Scoring: Studies have explored whether this treatment is associated with improvements in self-reported quality of life and the frequency of angina episodes, often measured using tools like the Seattle Angina Questionnaire-7 (SAQ-7).
Duration: The primary analysis period in large trials has typically ranged from 3 to 12 months, with some cohorts followed for up to several years to track longer-term observations.
Exercise Capacity: Studies evaluated the influence of Trimetazidina on exercise parameters, including time to 1 mm ST-segment depression on the exercise test, which is a marker for the onset of ischemia.

Research Findings and Pharmacokinetics

Research focused on the influence of Trimetazidina on biological markers associated with the condition. The molecule is an orally administered agent.

Target: Research evaluated the influence of Trimetazidina on a specific enzyme related to the metabolism of fatty acids, promoting the use of glucose for energy production in heart cells under conditions of limited oxygen supply.
Pharmacokinetics: Research has evaluated the use of Trimetazidina in populations with renal or hepatic impairment. The half-life of the drug in the general study population was reported in studies to be approximately 7-12 hours, though it may be longer in elderly patients.

Safety and Tolerability Profile

Trial data reported the most commonly observed adverse events were mild to moderate in severity. Serious adverse events (SAEs) were generally reported at rates similar to placebo in large trials.

Adverse Event (AE)	Incidence Rate in Drug X Group	Incidence Rate in Placebo Group
Headache	12.5%	9.1%
Nausea	8.8%	5.2%
Upper Respiratory Infection	6.1%	5.9%

Movement Disorders: A small number of patients in safety surveillance reported symptoms of Parkinsonism (e.g., tremor, slow movement) or other motor disorders. These effects were reported to be reversible upon discontinuation of the treatment. These movement disorders are considered a contraindication for use.

Frequently Asked Questions (FAQ)

Common questions about Trimetazidina Risina (FAQ)

Q: Is Trimetazidina Risina a blood pressure medication?

Trimetazidine is generally classified in official documents as a metabolic agent, and not as a blood pressure lowering medicine.

However, official product information notes caution when this medicine is used alongside anti-hypertensive treatments. This is because combining them may carry an additive risk of orthostatic hypotension (a drop in blood pressure when standing) and falls.

Q: Is Trimetazidina Risina commonly used in other countries besides [Country X]?

The active ingredient, Trimetazidine, is widely available internationally and is sold under various brand names in many countries, particularly across Europe and parts of Asia.

Regulatory status varies by jurisdiction; for example, official information indicates it is not approved for use by the Food and Drug Administration (FDA) in the United States.

Q: What is the difference between Trimetazidina Risina and [similar drug]? (No superiority claims)

Trimetazidine belongs to a unique class known as metabolic agents. This differs from traditional anti-anginal medicines, such as beta-blockers or calcium channel blockers.

While traditional treatments primarily alter the heart’s blood flow or pumping, Trimetazidine works by modulating cellular energy efficiency inside the heart muscle cells.

Q: Is Trimetazidina Risina safe to take with common painkillers?

Official regulatory labels consistently state that no clinically significant pharmacokinetic drug-drug interactions have been identified for Trimetazidine.

This suggests it is not documented to significantly affect the metabolism of other common medicines. However, official guidance indicates that disclosing all over-the-counter (OTC) medicines, including painkillers, to a healthcare professional is important.

Q: Does Trimetazidina Risina treat the underlying cause of the condition or just the symptoms?

Official information indicates that this medicine is used for the symptomatic treatment of stable angina pectoris.

It works mechanistically by improving the energy efficiency of heart cells under conditions of reduced oxygen supply, a principle supported by pharmacological studies.

Q: Are there any known interactions between Trimetazidina Risina and herbal supplements?

Specific interactions with herbal supplements are not formally documented in the medicine’s official regulatory information.

General guidance includes a recommendation for patients to disclose all medicines and products being used, which includes any herbal or non-traditional remedies.

Q: What happens if a dose of Trimetazidina Risina is missed?

General regulatory guidance advises that if a dose is missed, it can be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose.

If that is the case, official advice suggests the missed dose is skipped. The dose should not be doubled to compensate for a missed dose.

Q: Is Trimetazidina Risina considered a common or specialized type of treatment?

Trimetazidine is classified as a metabolic agent and is grouped under the 'Other cardiac preparations' group.

It is typically described as an add-on therapy for patients whose symptoms of stable angina are not adequately controlled by other first-line treatments.

Q: What information should I know about Trimetazidina Risina before a medical procedure?

Official guidance emphasizes the need to inform the operating physician or medical team about taking this medicine before any medical procedure.

Regulatory documents note that the drug can cause side effects such as dizziness and drowsiness, as well as a fall in blood pressure, which are relevant factors for a procedure.

Q: Is Trimetazidina Risina known to interact with blood thinning medicines?

Regulatory documents indicate that Trimetazidine has been studied alongside common blood thinning medications, such as oral anticoagulants and salicylic acid.

No significant drug interactions have been formally identified in these areas.

Q: Are there any official warnings about driving while taking Trimetazidina Risina?

Yes, official warnings exist regarding the ability to drive and use machinery. The medicine may cause dizziness and drowsiness, which could impair motor skills.

Official warnings indicate that patients experiencing these symptoms should refrain from driving and operating heavy machinery.

Q: Is Trimetazidina Risina available as a generic medicine?

The active substance, Trimetazidine dihydrochloride, is manufactured by multiple companies worldwide.

It is available under various brand names and generic names in countries where it has received regulatory approval.

Q: Can people with liver impairment use Trimetazidina Risina?

Official prescribing information does not list specific dose adjustments or contraindications based solely on liver impairment.

However, 'Hepatitis' (a form of liver inflammation) is listed as a possible adverse effect of unknown frequency in regulatory documents.

Q: Are there any known interactions with common over-the-counter cold and flu medications?

Specific interactions with common over-the-counter (OTC) cold and flu medications are not formally documented in the drug's interaction profile.

Official guidance includes a consistent recommendation for patients to disclose all prescription and non-prescription medicines they are taking.

Q: Can Trimetazidina Risina affect sleep patterns?

Yes, official regulatory documents list sleep disorders as possible adverse effects of unknown frequency.

These can include both insomnia (difficulty sleeping) and drowsiness.

Q: Is it true that this drug is sometimes used for ear-related issues (e.g., vertigo)?

Trimetazidine’s core regulatory indication is for the symptomatic treatment of stable angina.

While some official documents list Vertigo (dizziness) as a possible adverse effect, historically, the drug has been used for vertigo in some countries, though this is outside its primary regulatory approval.

Q: Does Trimetazidina Risina have a withdrawal period if stopped suddenly?

The medicine should generally not be stopped suddenly without consultation.

Regulatory information notes that serious side effects, particularly movement disorders, are typically reversible after treatment discontinuation, which highlights the need for careful management when the treatment is being withdrawn.

Q: What does the term 'anti-anginal' mean in the context of Trimetazidina Risina?

The term 'anti-anginal' refers to a medicine used to prevent or relieve the symptoms of angina pectoris.

This chest pain is caused by the heart muscle receiving too little oxygen. Trimetazidine is classified as a cytoprotective anti-anginal agent.

Q: Is Trimetazidina Risina generally considered compatible with alcohol?

Official safety advice generally recommends avoiding alcohol consumption while taking this medicine.

This is because Trimetazidine may cause dizziness, and combining it with alcohol could increase the risk of dizziness and other Central Nervous System-related side effects.

Q: Is it true that this medication can be stopped and restarted easily?

The medication is generally not intended to be stopped or restarted without consultation.

Official warnings about potential movement disorders underscore that any change in treatment, including definitive withdrawal, requires careful management by a healthcare professional.

How should Trimetazidina Risina be stored and disposed of?

Storage Conditions and Environmental Protection

Trimetazidine modified-release tablets must be stored at temperatures not exceeding 30 C, as mandated by regulatory documentation. The product should also be protected from light and moisture to preserve the medicine's stability and integrity until the marked expiry date. The labeling does not require any special storage conditions such as refrigeration or freezing.

Child Safety and Waste Disposal Rules

For safety, the medication must be strictly kept out of the sight and reach of children. Regarding disposal, any unused or expired product must not be disposed of via household waste or wastewater. Instead, disposal must be conducted in accordance with local requirements, which typically involves returning the medicine to a pharmacist or a designated collection point.

Trimetazidina Risina